Developability studies before initiation of process development

Improving manufacturability of monoclonal antibodies

Xiaoyu Yang BioProcess Development; Merck Research Laboratories; Union, NJ USA

Wei Xu BioProcess Development; Merck Research Laboratories; Union, NJ USA

Svetlana Dukleska BioProcess Development; Merck Research Laboratories; Union, NJ USA

Sabrina Benchaar Discovery Biologics; Merck Research Laboratories PaloAlto; Palo Alto, CA USA

Selina Mengisen BioProcess Development; Merck Research Laboratories; Union, NJ USA

Valentyn Antochshuk BioProcess Development; Merck Research Laboratories; Summit, NJ USA

Jason Cheung BioProcess Development; Merck Research Laboratories; Summit, NJ USA

Leslie Mann BioProcess Development; Merck Research Laboratories; Union, NJ USA

Zulfia Babadjanova BioProcess Development; Merck Research Laboratories; Union, NJ USA

Jason Rowand BioProcess Development; Merck Research Laboratories; Union, NJ USA

Rico Gunawan BioProcess Development; Merck Research Laboratories; Union, NJ USA

Alexander McCampbell Molecular biomarkers; Merck Research Laboratories; West Point, PA USA

Maribel Beaumont Discovery Biologics; Merck Research Laboratories PaloAlto; Palo Alto, CA USA

David Meininger Discovery Biologics; Merck Research Laboratories PaloAlto; Palo Alto, CA USA

Daisy Richardson BioProcess Development; Merck Research Laboratories; Union, NJ USA

Alexandre Ambrogelly BioProcess Development; Merck Research Laboratories; Union, NJ USACorrespondence[email protected]